The Food and Drug Administration (FDA) has approved selumetinib (Koselugo) to treat children with neurofibromatosis 1 (NF1), a genetic disorder that causes tumors, called plexiform neurofibromas, to form throughout the nervous system.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/3ciNftX
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/3ciNftX